These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37884171)

  • 21. [Epigenetic dysregulation in myelodysplastic syndrome].
    Sashida G; Iwama A
    Rinsho Ketsueki; 2015 Feb; 56(2):111-8. PubMed ID: 25765789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular alterations governing predisposition to myelodysplastic syndromes: Insights from Shwachman-Diamond syndrome.
    Shimamura A
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101252. PubMed ID: 33762106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Tremblay D; Sokol K; Bhalla S; Rampal R; Mascarenhas JO
    Oncology (Williston Park); 2018 Apr; 32(4):e38-e44. PubMed ID: 29684235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.
    Damm F; Chesnais V; Nagata Y; Yoshida K; Scourzic L; Okuno Y; Itzykson R; Sanada M; Shiraishi Y; Gelsi-Boyer V; Renneville A; Miyano S; Mori H; Shih LY; Park S; Dreyfus F; Guerci-Bresler A; Solary E; Rose C; Cheze S; Prébet T; Vey N; Legentil M; Duffourd Y; de Botton S; Preudhomme C; Birnbaum D; Bernard OA; Ogawa S; Fontenay M; Kosmider O
    Blood; 2013 Oct; 122(18):3169-77. PubMed ID: 24047651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes.
    Kwon A; Weinberg OK
    Clin Lab Med; 2023 Dec; 43(4):657-667. PubMed ID: 37865509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies.
    Gaymes TJ; Mohamedali AM; Patterson M; Matto N; Smith A; Kulasekararaj A; Chelliah R; Curtin N; Farzaneh F; Shall S; Mufti GJ
    Haematologica; 2013 Sep; 98(9):1397-406. PubMed ID: 23349304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
    Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
    Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
    Stahl M; Gore SD; Vey N; Prebet T
    Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia.
    Kao HW; Sanada M; Liang DC; Lai CL; Lee EH; Kuo MC; Lin TL; Shih YS; Wu JH; Huang CF; Ogawa S; Shih LY
    Neoplasia; 2011 Nov; 13(11):1035-42. PubMed ID: 22131879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival.
    Bödör C; Renneville A; Smith M; Charazac A; Iqbal S; Etancelin P; Cavenagh J; Barnett MJ; Kramarzová K; Krishnan B; Matolcsy A; Preudhomme C; Fitzgibbon J; Owen C
    Haematologica; 2012 Jun; 97(6):890-4. PubMed ID: 22271902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.
    Sutandyo N; Mulyasari R; Kosasih A; Rinaldi I; Louisa M; Kevinsyah AP; Winston K
    Asian Pac J Cancer Prev; 2022 Apr; 23(4):1107-1116. PubMed ID: 35485665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
    Forghieri F; Paolini A; Morselli M; Bigliardi S; Bonacorsi G; Leonardi G; Coluccio V; Maccaferri M; Fantuzzi V; Faglioni L; Colaci E; Soci F; Nasillo V; Messerotti A; Arletti L; Pioli V; Zucchini P; Quadrelli C; Corradini G; Giacobbi F; Vallerini D; Riva G; Barozzi P; Lagreca I; Marasca R; Narni F; Mecucci C; Ottaviani E; Martinelli G; Falini B; Luppi M; Potenza L
    Leuk Lymphoma; 2015; 56(11):3222-6. PubMed ID: 25813079
    [No Abstract]   [Full Text] [Related]  

  • 33. Myelodysplastic Syndromes: How to Recognize Risk and Avoid Acute Myeloid Leukemia Transformation.
    Hospital MA; Vey N
    Curr Oncol Rep; 2020 Jan; 22(1):4. PubMed ID: 31974774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.
    Shih AH; Chung SS; Dolezal EK; Zhang SJ; Abdel-Wahab OI; Park CY; Nimer SD; Levine RL; Klimek VM
    Haematologica; 2013 Jun; 98(6):908-12. PubMed ID: 23349305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia.
    Martín-Izquierdo M; Abáigar M; Hernández-Sánchez JM; Tamborero D; López-Cadenas F; Ramos F; Lumbreras E; Madinaveitia-Ochoa A; Megido M; Labrador J; Sánchez-Real J; Olivier C; Dávila J; Aguilar C; Rodríguez JN; Martín-Nuñez G; Santos-Mínguez S; Miguel-García C; Benito R; Díez-Campelo M; Hernández-Rivas JM
    Haematologica; 2021 Aug; 106(8):2215-2223. PubMed ID: 32675227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression.
    Okamoto S; Tsujioka T; Suemori S; Kida J; Kondo T; Tohyama Y; Tohyama K
    Cancer Sci; 2016 Sep; 107(9):1302-14. PubMed ID: 27311589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation in TET2 in myeloid cancers.
    Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
    N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations.
    West AH; Godley LA; Churpek JE
    Ann N Y Acad Sci; 2014 Mar; 1310(1):111-8. PubMed ID: 24467820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia.
    Liao R; Xu Y; Chen M; Chen X; Zhan X; Sun J
    Hematology; 2013 Jul; 18(4):191-7. PubMed ID: 23321417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
    Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC
    Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.